Possible side effects 5. Possible side effects 5. Urinalysis was positive for red blood cells, hemoglobin, and myoglobin. Our Cubicin (daptomycin) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. Daptomycin, a cyclic lipopeptide with rapid bactericidal activity, is approved at doses of 4 mg/kg and 6 mg/kg for the treatment of its respective indications [i.e. On binding, the lipophilic moiety (i.e., Initial clinical studies were suspended due to concerns regarding skeletal muscle toxicity, manifested by muscle weakness and elevated levels of creatine phosphokinase (CPK). complicated skin and soft-tissue infections (cSSTIs) caused by Gram-positive bacteria; and Staphylococcus aureus bacteraemia associated with right-sided infective endocarditis (RIE) or cSSTIs, or RIE due to S. aureus]. Gram-negative infections included cholangitis, alcoholic pancreatitis, sternal osteomyelitis/mediastinitis, bowel infarction, recurrent Crohn’s disease, recurrent line sepsis, and recurrent urosepsis caused by a number of different Gram-negative bacteria.The rates of the most common adverse reactions, organized by System Organ Class (SOC), observed in adult patients with The following reactions, not included above, were reported as possibly or probably drug-related in the CUBICIN-treated group:In Phase 3 trials of community-acquired pneumonia (CAP) in adult patients, the death rate and rates of serious cardiorespiratory adverse events were higher in CUBICIN-treated patients than in comparator-treated patients. By continuing you agree to the Copyright © 2020 Elsevier B.V. or its licensors or contributors. This is not a complete list of side effects and others may occur. Daptomycin is used in adults and in children and adolescents (age … Call your doctor for medical advice about side effects. Call your doctor for medical advice about side effects. She progressively recovered.The pharmacokinetics of daptomycin 4 mg/kg have been studied in moderately obese adults (BMI over 25 and under 40 kg/mOther analogs, which vary on the lipophilic moiety, are concomitantly produced in the fermentations. You may report side effects to FDA at 1-800-FDA-1088.This is not a complete list of side effects and others may occur. Contents of the pack and other information 1.What Daptomycin Clonmel is and what it is used for The active substance in Daptomycin Clonmel powder for solution for injection or infusion is daptomycin. The symptoms resolved within 3 days and CPK returned to normal within 7 to 10 days after treatment was discontinued [see The safety of CUBICIN was evaluated in one clinical trial (in cSSSI), which included 256 pediatric patients (1 to 17 years of age) treated with intravenous CUBICIN and 133 patients treated with comparator agents. Finally, daptomycin seems to have a favourable side-effect profile, and it might be used to treat patients who cannot tolerate other antibiotics. Daptomycin Clonmel … Daptomycin is used in adults and in … Infections were reported during treatment and during early and late follow-up. These differences were due to lack of therapeutic effectiveness of CUBICIN in the treatment of CAP in patients experiencing these adverse events [see In Phase 3 cSSSI trials of adult patients receiving CUBICIN at a dose of 4 mg/kg, elevations in CPK were reported as clinical adverse events in 15/534 (2.8%) CUBICIN-treated patients, compared with 10/558 (1.8%) comparator-treated patients. Tell your doctor if you have serious side effects of Cubicin including:Cubicin may interact with blood thinners, tobramycin, or It is not known whether this drug passes into breast milk. Daptomycin is an acceptable alternate to vancomycin; one trial including 45 patients with skin and soft tissue infection due to MRSA noted similar rates of clinical success between daptomycin and vancomycin… alternative agents with activity against MRSA may be based on logistics of administration, side-effect profiles, availability, and cost All of the alternative agents have been …